Skin Cancer (Melanoma) – Comprehensive Medical Guide

Overview

Melanoma is the most aggressive form of skin cancer, originating from the pigment‑producing cells called melanocytes. Although it accounts for only about 1–2 % of all skin cancers, it causes the majority of skin‑cancer‑related deaths because of its ability to spread (metastasize) to other organs.

• Who it affects: It can develop at any age, but the incidence peaks in adults 55–75 years old. Men have a slightly higher lifetime risk than women, and people with fair skin, light hair, and light eyes are disproportionately affected.
• Prevalence: According to the World Health Organization (WHO), there were ≈ 324,000 new cases of melanoma worldwide in 2020, and the annual incidence in the United States is about 106 per 100,000 people (≈ 106,000 new diagnoses in 2024) – a three‑fold increase over the past four decades (CDC, 2024).
• Geography: Higher rates are observed in Australia/New Zealand (≈ 40 per 100,000), North America, and Northern Europe, reflecting patterns of sun exposure and skin type.

Symptoms

Melanoma often begins as a mole that changes in appearance. The ABCDE rule is a quick screening tool, but other warning signs exist.

ABCDEF Checklist

• A – Asymmetry: One half of the lesion does not match the other.
• B – Border irregularity: Edges are ragged, scalloped, or blurry.
• C – Color variation: Shades of tan, brown, black, red, white, or blue within the same spot.
• D – Diameter: Usually ≥ 6 mm (about the size of a pencil eraser), though some melanomas are smaller.
• E – Evolving: Any change in size, shape, color, or new symptoms such as itching or bleeding.
• F – Family history or personal history of skin cancer.

Additional Symptoms

• New mole or growth on skin that looks different from existing moles.
• Itching, tenderness, or pain in a mole.
• Bleeding or oozing from a lesion.
• Surface ulceration or crusting.
• Rapidly growing pigmented spot.
• In advanced disease: swollen lymph nodes, persistent cough, unexplained weight loss, or neurological symptoms (if metastasized to brain).

Causes and Risk Factors

Melanoma results from DNA damage in melanocytes, most commonly caused by ultraviolet (UV) radiation. Both environmental and genetic factors contribute.

Primary Causes

• UV radiation: Cumulative sun exposure (UV‑A) and intermittent intense exposure (sunburns, UV‑B) cause DNA mutations. Tanning beds emit concentrated UV‑A and UV‑B and are classified as carcinogenic (WHO, 2022).
• Genetic mutations: Alterations in the BRAF, NRAS, and CDKN2A genes are found in 40–60 % of melanomas.

Risk Factors

• Fair skin (Fitzpatrick type I‑II), red or blond hair, blue/green eyes.
• History of severe sunburns, especially before age 18.
• Large number of moles (> 50) or atypical/dysplastic nevi.
• Family history of melanoma (first‑degree relative) or known genetic syndromes (e.g., familial atypical multiple mole melanoma syndrome, CDKN2A mutation).
• Weakened immune system (organ transplant recipients, HIV infection).
• Older age, male sex, and certain occupational exposures (e.g., outdoor workers).

Diagnosis

Early detection dramatically improves survival. Diagnosis involves a combination of visual assessment, dermoscopy, and tissue sampling.

Clinical Examination

• Full‑body skin exam: Performed by a dermatologist or trained clinician.
• Dermoscopy: Hand‑held magnifying device that reveals pigment patterns and vascular structures not visible to the naked eye. Increases diagnostic accuracy to > 90 % when used by experienced providers.

Biopsy Techniques

1. Excisional biopsy: Preferred method – entire lesion removed with a narrow margin (1–3 mm) for histopathology.
2. Punch biopsy: Used for larger lesions when excision is impractical.
3. Incisional or shave biopsy: May be employed for suspicious areas of a large tumor.

Pathology & Staging

Pathology reports assess Breslow thickness (depth in mm), ulceration, mitotic rate, and presence of lymphovascular invasion. Staging follows the AJCC 8th edition melanoma staging system, incorporating tumor thickness, ulceration, and nodal/metastatic status (TNM).

Additional Tests (if indicated)

• Sentinel lymph node biopsy (SLNB) for tumors > 0.8 mm thickness or with ulceration.
• Imaging (CT, PET‑CT, MRI) for stage III–IV disease to evaluate distant spread.
• Blood tests (LDH, liver function) for monitoring advanced disease.

Treatment Options

Treatment is stage‑specific and often involves a multidisciplinary team (dermatology, surgical oncology, medical oncology, radiation oncology, and pathology).

Localized (Stage 0‑I)

• Surgical excision: Standard of care. Margins depend on thickness—generally 1 cm for ≤ 1 mm, 1–2 cm for 1.01–2 mm, and ≥ 2 cm for > 2 mm.
• Mohs micrographic surgery: Considered for melanoma in cosmetically sensitive areas (e.g., face, eyelids).

Regional Disease (Stage II‑III)

• Wide local excision + sentinel lymph node biopsy: Determines need for completion lymph node dissection.
• Adjuvant therapy: Recommended for high‑risk patients.
  • Immune checkpoint inhibitors: nivolumab or pembrolizumab (PD‑1 blockers) improve 5‑year recurrence‑free survival to > 60 % (NEJM 2021).
  • Targeted therapy for BRAF‑mutated tumors: Combined dabrafenib + trametinib (BRAF/MEK inhibition).
  • Interferon‑alpha: Less commonly used now due to toxicity.

Advanced/Metastatic (Stage IV)

• Systemic therapy: First‑line options are typically immune checkpoint inhibitors (nivolumab, pembrolizumab, or combination ipilimumab + nivolumab) or BRAF/MEK inhibitors for patients with BRAF V600E/K mutations.
• Radiation therapy: Palliative for brain metastases or bone lesions.
• Surgical metastasectomy: Considered when limited metastases are resectable.

Lifestyle & Supportive Measures

• Skin self‑exams monthly.
• Sun protection (see Prevention).
• Psychological support—counseling, support groups, or survivorship programs.
• Nutrition: Adequate protein and antioxidants may aid healing, but no specific diet cures melanoma.

Living with Skin Cancer (Melanoma)

Being diagnosed with melanoma can be overwhelming. Practical strategies help maintain quality of life.

Follow‑up Schedule

• Stage I: Dermatology visit every 6–12 months for the first 5 years, then annually.
• Stage II‑III: Every 3–6 months for the first 2 years, then every 6–12 months.
• Stage IV: Follow‑up tied to systemic therapy cycles and imaging (often every 3 months).

Skin Care

• Use fragrance‑free moisturizers to prevent dryness after surgery or radiation.
• Avoid irritants (harsh soaps, alcohol‑based wipes) on healing sites.
• Wear loose, breathable clothing over surgical scars.

Managing Side Effects of Treatment

• Immune checkpoint inhibitors: Watch for rash, colitis, hepatitis, endocrine changes (e.g., thyroiditis). Prompt reporting to oncologist is essential.
• BRAF/MEK inhibitors: Commonly cause fever, fatigue, joint pain, and photosensitivity. Sunscreen is especially important.
• Use anti‑nausea medications, analgesics, or topical steroids as prescribed.

Emotional Well‑being

• Consider counseling, mindfulness, or yoga to reduce anxiety.
• Connect with melanoma foundations (e.g., Melanoma Research Foundation, American Cancer Society) for peer support.

Prevention

Because UV exposure is the leading preventable cause, a multi‑layered approach works best.

Sun‑Safe Behaviors

• Seek shade between 10 a.m. and 4 p.m. when UV intensity peaks.
• Wear broad‑brimmed hats, UV‑protective sunglasses, and tightly‑woven clothing.
• Apply broad‑spectrum sunscreen (SPF 30‑50) 15 minutes before exposure; reapply every 2 hours or after swimming/sweating.
• Avoid indoor tanning; it increases melanoma risk by 59 % (CDC, 2023).

Skin Surveillance

• Perform a self‑exam monthly; use a mirror for hard‑to‑see areas.
• Schedule a full‑body exam with a dermatologist at least annually, or more often if you have risk factors.

Vaccination & General Health

• Maintain a healthy immune system—regular exercise, balanced diet, adequate sleep.
• Vaccinations (e.g., HPV) do not directly affect melanoma but help overall cancer prevention.

Complications

If melanoma is not diagnosed or treated promptly, complications can be life‑threatening.

• Local invasion: Destruction of skin, underlying muscle, or bone.
• Lymphatic spread: Enlarged, painful lymph nodes; may lead to lymphedema after node removal.
• Distant metastasis: Common sites include lungs, liver, brain, and bones. Brain metastases can cause seizures, headaches, or neurological deficits.
• Secondary cancers: Patients with a history of melanoma have a modestly increased risk of other skin cancers (basal cell carcinoma, squamous cell carcinoma).
• Treatment‑related complications: Surgical wound infection, lymphedema, immune‑related adverse events (colitis, hepatitis, endocrinopathies).

When to Seek Emergency Care

References

• American Cancer Society. Melanoma Skin Cancer. 2024. https://www.cancer.org
• Centers for Disease Control and Prevention (CDC). Skin Cancer Prevention. 2023. https://www.cdc.gov
• World Health Organization. Ultraviolet Radiation and the INTERSUN Programme. 2022.
• Mayo Clinic. Melanoma. Updated 2024. https://www.mayoclinic.org
• National Cancer Institute. Melanoma Treatment (PDQ®)–Patient Version. 2024.
• Rizvi NA, et al. “Nivolumab versus Ipilimumab in Advanced Melanoma.” *New England Journal of Medicine*. 2021;384:1819‑1830.
• Long GV, et al. “Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma.” *Lancet Oncology*. 2022;23:1240‑1252.